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A 13-year-old patient with cystic fibrosis was diagnosed with anaplastic large cell lymphoma. At the same time colonization with
Mycobacterium chelonae was detected in sputum cultures. Despite massive immunosuppression, the patient did not show evidence of
mycobacterial invasive disease. Colonisation persisted for 18 months after discontinuation of chemotherapy and was not detected in the 6
years thereafter. This case highlights the dilemma of differentiating between colonisation and infection if mycobacteria are found in CF
sputum samples.
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Nontuberculous mycobacteria are discovered with in-
creasing frequency in patients with cystic fibrosis (CF). The
prevalence varies among centres with same centres report-
ing prevalence of 13% [1–3]. Most of the isolates can be
classified as Mycobacterium avium (M. avium) complex,
followed by Mycobacterium abscessus (M. abscessus) [2].
Other isolates are encountered less frequently. Both M.
abscessus and M. chelonae are often multiresistant in in
vitro tests [4,5] and have been reported to be associated with
more significant pulmonary disease [6,7].
Clinical significance of mycobacteria other than tuber-
culosis (MOTT) detected in sputum of CF patients,
especially in the context of immunosuppressive therapy, is
quite unclear. There have been some reports ofM. abscessus
infection following lung transplantation, but to our knowl-
edge no report on the effect of immunosuppressive therapy1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
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sputum cultures. We here describe the clinical course of a
CF patient with both lymphoma and airway colonisation
with M. chelonae, who underwent high dose immunosup-
pressive chemotherapy for anaplastic lymphoma.2. Case report
The boy was born in Sicily in 1984 and, at 8 months of
age, was diagnosed with a history of recurrent broncho-
pulmonary infections after moving to Germany. He deve-
loped chronic Pseudomonas aeruginosa (P. aeruginosa)
infection in the first year of live and had symptoms of
airway obstruction up to the age of 2 years. The following
course of illness was stable without any significant
problems. At first presentation to our hospital at the age
of 12 years, he was doing well with a BMI of 17 and normal
lung function (FEV1 87% predicted). His sputum demon-
strated chronic infection with four different strains of
mucoid P. aeruginosa.
2 years later, he presented with symptoms of constipa-
tion to another hospital. On this occasion, the mediastinum5 (2006) 133 – 136ed by Elsevier B.V. All rights reserved.
Fig. 1. CT scan at the time of neutropenia and fever showing infiltrates in
the right upper lobe.
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control was recommended. One month later, he was
readmitted to hospital with a painful inguinal mass which
was considered to be due to bacterial infection. Intravenous
antibiotic therapy with ceftazidime and tobramycin admin-
istered over a 2-week period was ineffective and a biopsy
was performed. Three lymph nodes were removed; histol-
ogy revealed a large cell anaplastic T-cell-lymphoma.
Extensive diagnostic workup showed no involvement of
other lymph node regions or organ systems nor of CNS or
bone marrow. A HRCT of the chest revealed bronchiectasis
mainly in the right upper lobe but no evidence of
mediastinal involvement.
Sputum cultures at that time continued to grow four
different strains of P. aeruginosa as well as M. chelonae
resistant to all available tuberculostatic drugs. Methods for
mycobacteria culturing, species identification within the
M. chelonae complex, as well as drug susceptibility
testing of mycobacteria were used as recently described
[8,9].
In view of the patient’s stable pulmonary status, it was
decided to start chemotherapy without instituting specific
therapy for mycobacteria. To prevent exacerbation of his
chronic P. aeruginosa infection, the patient was started on
intravenous antibiotic therapy with ceftazidime and tobra-
mycin, which was later switched to meropenem and
tobramycin and maintained throughout immunosuppressive
therapy. The patient was treated according to the NHL-BFM
95, which includes dexamethasone (55–10 mg/m2/day)
and CPM (2200 mg/m2/day) for 5 days followed by high
dose MTX (1500 mg/m2/day), ARA-C (4150 mg/m2/
day), IFO (5800 mg/m2/day) and VP16 (2100 mg/m2/
day) in the first block (5 days). In the second block (5 days),
IFO and VP16 and ARA-C are replaced by CPM (5200
mg/m2/day) and DOX (225 mg/m2/day). Both blocks
include daily dexamethasone applications (10 mg/m2/day).
In addition to intravenous chemotherapy intrathecal therapy
with prednisone, MTX and ARA-C was administered.
ARA-C was discontinued after the first dose because of a
toxic–allergic reaction. Otherwise, the first block was well
tolerated despite neutropenia with a nadir of 220/nl for 5
days. At end of the course M. chelonae was still detected in
sputum cultures. Remarkably, at that time acid-fast smears
were as well found to be positive.
Two weeks later the second course of chemotherapy was
administered that resulted in neutropenia with a nadir of 64/
nl neutophils for 5 days. The patient developed mucositis
and required total parenteral nutrition. In addition, he
became symptomatic with fevers up to 40 -C and worsening
of pulmonary symptoms. A chest CT scan showed
infiltration of the right upper lobe (Fig. 1). Sputum cultures
revealed Candida albicans as well as Staphylococcus
epidermidis; teicoplanin plus amphotericin B was added to
the antibiotic therapy with meropenem and tobramycin. The
pulmonary situation was re-stabilized and there was gradual
improvement of the right upper lobe infiltrates.Four further sputum cultures over the subsequent 18
months yielded M. chelonae. During this time period, the
patient received several courses of oral cefaclor for mild
pulmonary exacerbations in addition to continuous colistin
inhalation twice daily, but no specific therapy for mycobac-
teria. Subsequently, no mycobacteria were found on
multiple cultures (including 2 bronchoalveolar lavage
samples) for the next 6 years.
The patient is now 20 years old and clinically stable with
a BMI of 20. His airways are colonized with a single P.
aeruginosa strain. He attains normal lung function with an
FEV1 between 80% and 100% predicted. There is no
evidence for recurrence of lymphoma to date.3. Discussion
This case highlights the diagnostic dilemma in patients
with CF found to be positive for mycobacteria other than
tuberculosis. The patient described in this report did well
despite massive immunosuppression and subsequently
cleared the infection spontaneously. The scenario of upper
lobe infiltrates in a febrile patient known to be colonised
with mycobacteria could have prompted us to initiate
treatment and we would then have attributed the improve-
ment to the intervention. Therefore, unless there is
histologic prove of caseous granulomas or tissue invasion
[10], it appears to be virtually impossible to differentiate
relevant infection from pure colonisation in this patient
population with underlying lung disease and concomitant
chronic bacterial infection [11].
CF patients have an increased risk to develop carcinoma
of the gastrointestinal tract, whereas other malignancies
occur at a similar rate as in the general population [12–14].
More specifically, the risk for lymphoma is not increased in
E. Tschiedel et al. / Journal of Cystic Fibrosis 5 (2006) 133–136 135CF patients [12,13]. Against this background we classify
our case as a sporadically occurred lymphoma in a patient
with CF.
Immunosuppression as necessary treatment for different
diseases is a known risk factor for reactivating tuberculosis
from latent to active disease [15] and also for new infection
with mycobacteria [10,16].
The clinical significance of detecting mycobacteria
among CF patients is not yet firmly established. Criteria
for relevant disease in other patient groups are: 1) clinical
signs and symptoms such as chronic cough, sputum
production, fatigue, malaise, dyspnea, fever, hemoptysis
and weight loss; 2) multiple positive sputum or bronchial
wash cultures and/or smears (3 positive cultures or 2
positive cultures and 1 positive smear or 1 positive culture
and 1 highly positive smear or histopathology of biopsy
shows mycobacterial features or contents NTM); and 3)
compatible radiographic findings as multilobar, patchy,
reticulonodular or mixed interstitial–alveolar infiltrates with
upper lobe predominance in chest radiography and/or
cylindrical bronchiectasis and/or multiple small (<5 mm)
nodules in HRCT [2,11].
So far there are no definitive criteria defined for patients
with underlying CF because clinical signs as symptoms as
well as radiographic findings can overlap between those
caused by CF and by NTM infection. Definite proof
depends upon histological proof of the infection, which is
rarely attained in these patients. Therefore, only repeated
positive cultures or the combination with clinical deteriora-
tion and/or the mentioned radiographic findings that cannot
be attributed to another cause are a solid basis for founded
suspicion of infection with NTM. There is also some
evidence suggesting that patients with positive results of
acid-fast smears are more likely to be infected than
colonized [7,17–19].
There are no reports related to the NTM infection in
paediatric patients with lymphoma, but individual cases
have been published in patients with leukaemia [20,21]. In
contrast to our case, all those patients were treated with
antimicrobial therapy directed against mycobacteria. In all
except one patient, NTM was not detected after the
therapeutic intervention. Our case highlights the known
phenomenon that this transient colonisation can clear
spontaneously. It is therefore difficult to define from these
reports whether the therapeutic invention changed the
natural course of the disease.
Immunosuppression is generally known as a risk factor
for exacerbation of mycobacterial colonisation into invasive
infection [15] and mycobacteria in the lung are regarded as a
relative contraindication for lung transplantation in CF
because of the risk of disseminating mycobacteria infection
under the immunosuppressive therapy. Some authors
recommend therapy of nonsymptomatic mycobacterial
colonisation before starting any immunosuppressive therapy
[15]. In contrast to that, Kesten and Chaparro describe two
cases of new colonization with mycobacteria under immu-nosuppressive therapy after lung transplantation with
obviously indolent disease so that no changes in immuno-
suppression were required [22]. They drew the conclusion
that no therapy of indolent colonization is necessary. The
outcome of our case and the experience of Suryanarayan et
al. [21] and Levendoglu-Tugal et al. [20] also support this
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